00:25:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-04-19 Ordinarie utdelning LYTIX 0.00 NOK
2024-04-18 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-04-19 Ordinarie utdelning LYTIX 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-22 Ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar nya cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.
2023-10-09 15:00:00
Oslo, 9 October 2023. Lytix Biopharma - Lytix Biopharma AS ("Lytix") (Euronext
Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr
Henrik Jespersen, Head of Melanoma Oncology at Oslo University Hospital, will
give a presentation of the NeoLIPA trial with LTX-315 at the 15th Nordic
Melanoma Meeting (Reykjavik, 11-13 October 2023).

The title of the presentation is: Neoadjuvant LTX-315 in combination with
pembrolizumab in resectable stage III/IV melanoma (NeoLIPA trial): Protocol for
a single center phase II open label study.

NeoLIPA is a Phase II open label clinical trial of neoadjuvant LTX-315 in
combination with Keytruda® (pembrolizumab), in 27 patients with clinically
detectable and resectable stage III-IV melanoma.
Lytix Biopharma's lead product, LTX-315, is a first-in-class molecule
representing a new and superior therapeutic principle to kill cancer cells and
boost anti-cancer immunity, with the potential to be the ideal combination
partner with other types of immunotherapy. Neoadjuvant checkpoint inhibition has
been shown to significantly reduce the risk of relapse for high-risk melanoma
compared to adjuvant therapy, however many patients still have little effect of
the treatment. Consequently, there is a need for novel, more efficient
neoadjuvant treatment regimens, and in the NeoLIPA study LTX-315 will be added
to standard of care combined with pembrolizumab.

The presentation will hypothesize that intratumoral administration of the
LTX-315 will enhance the effect of pembrolizumab as a neoadjuvant treatment
prior to surgery for stage III or IV melanoma.

***
Dr. Øystein Rekdal, Chief Executive Officer at Lytix Biopharma, commented:
"Lytix's unique technology may offer a novel solution to one of the major
challenges in today's cancer treatment. This neoadjuvant study presents an
opportunity to demonstrate whether LTX-315 in combination with standard of care
treatment in neoadjuvant setting could enhance the clinical outcome in
early-stage melanoma patients."

Dr Henrik Jespersen, Head of Melanoma Oncology at Oslo University Hospital,
added: "With its proposed dual mode of action, LTX-315 is a promising drug for
combination with a PD-1 inhibitor in the neoadjuvant setting. By directly
killing cancer cells in the injected lesion, LTX-315 can shrink the tumor
locally before surgery and at the same time induce tumor specific immune
responses in the patient that potentially can reduce the risk of relapse of the
disease after surgery. "

***

For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communications Manager:
ole.peter.nordby@lytixbiopharma.com
Optimum Strategic Communications: Jonathan Edwards, Vici Rabbetts:
lytix@optimumcomms.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapy. LTX-315 targets cancer cells and disintegrates their
cell membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors
including PBM Capital, a US based, healthcare-focused investment firm.